Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ibuzatrelvir DDI with Dabigatran in Healthy Adults
NCT06693518Phase 1Completed
- Sponsor
- Pfizer
- Start
- Nov 2024
- Primary completion
- Jan 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of ibuzatrelvir in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Pfizer. Primary endpoints: Maximum Observed Plasma Concentration and Area Under the Concentration-Time Curve From Time Zero to Infinity. Started Nov 2024; status: completed.
02
Drugs
ibuzatrelvir
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT06693518.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06693518.